Stock screener

DMAC

Conviction 29HealthcareScan · Thu, Jun 25, 2026
DMAC$6.14-3.46%
ResistanceSupportVol 14
63 bars
Vol MA14 192.26K
Mar 26Apr 14May 1May 19Jun 8Jun 25
DiaMedica Therapeutics Inc.PHARMACEUTICAL PREPARATIONSwww.diamedica.com
Price6.14
Change-3.46%
Gap+3.22%
Rel volume1.12×
Avg volume180.32K
Avg $ vol1.04M
SMA 205.80
SMA 506.06
SMA 2007.17
Price vs 50+1.35%
Price vs 200-14.33%
MA stackmixed
50/200 cross
Supertrenddown · 6.40
RSI (14)56
MACD hist0.10
MACD crossbull · 6d
Stoch %K / %D61 / 78
ADX (14)17
+DI / −DI26 / 17
RSI divergenceBullish
MACD divergenceBullish
ATR %+5.93%
ADR %6.10%
52w high9.39
52w low3.57
From 52w high-34.61%
Above 52w low+71.99%
New 52w highNo
SqueezeOff
Bollinger width18.73%
%B0.82
Donchian pos61.09%
Donchian high6.71
Donchian low5.25
AVWAP (52w high)7.48
vs AVWAP high-17.86%
AVWAP (52w low)6.79
vs AVWAP low-9.53%
OBV trendFlat
Chaikin MF (20)-0.15
Today vs 20d1.12×
Avg vol (14d)192.26K
Avg vol (20d)180.32K
Avg $ vol (20d)1.04M
Market cap330.84M
RS 3m (vs SPY)-19.95%
RS 6m (vs SPY)-32.74%
RS line new highNo
Trend template4/8
Technical rank37.1
1 week+7.16%
1 month-2.85%
3 months-10.50%
6 months-27.25%
1 year+64.61%
YTD-22.57%
P/E-10.10
P/B7.00
P/S661.69
P/FCF-11.37
EPS-0.6500
Div yield
ROE-69.37%
ROA-61.73%
Debt/Eq
Current9.11
EV/EBITDA
Gross margin
Net margin
Rev growth0.00%
EPS growth-34.05%
Price target
Target upside
Analyst rating
Institutional
Ent. value325.98M
Revenue500K
Net income-10.04M
Gross profit
Free cash flow-29.1M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out53.88M
Employees35
ListedThu, Nov 29, 2007
Free float23.38M
Float %44.9%
Short interest4.87M
Days to cover30.4d
Short volume44.9%
Squeeze score70 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction29 / 100
Pattern quality
Tech rank37.1 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance6.54
Support5.30
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in DMAC

All disclosures →
No recent disclosed trades by Congress in DMAC. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in DMAC · 9 buys

InsiderSideShares
Kuntz Richard
Director · Stock Option (right to buy) · 2026-06-01
Grant40.41K
Parsons James T.
Director · Stock Option (right to buy) · 2026-06-01
Grant51.19K
Semba Charles Pauling
Director · Stock Option (right to buy) · 2026-06-01
Grant40.41K
Giuffre Randall Michael
Director · Stock Option (right to buy) · 2026-06-01
Grant40.41K
Kellen Scott
CFO & Secretary · Stock Option (right to buy) · 2026-06-01
Grant162K
O'Connor Daniel J.
Director · Stock Option (right to buy) · 2026-06-01
Grant40.41K
Krop Julie
Chief Medical Officer · Stock Option (right to buy) · 2026-06-01
Grant67.5K
Lewis Tanya
Director · Stock Option (right to buy) · 2026-06-01
Grant40.41K
Pauls Dietrich John
President & CEO · Stock Option (right to buy) · 2026-06-01
Grant380K

SEC filings

EDGAR filings in DMAC

EDGAR →

No recent SEC filings on file for DMAC.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.